FDA clears anticlotting drug Eliquis

The Food and Drug Administration says it has approved the anticlotting drug Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It's a potential blockbuster drug in a new category of medicines to prevent strokes and heart attacks.

The agency previously rejected the drug twice, most recently in June, awaiting additional data from company trials.

The FDA cleared the pill for treating the most common type of irregular heartbeat—atrial fibrillation—in patients at risk for strokes or dangerous clots.

About a quarter of all people aged 40 and older develop atrial fibrillation, a condition in which the heart's two upper chambers contract irregularly and don't pump blood efficiently.

Bristol-Myers Squibb shares rose 60 cents, or 2 percent, to $32.50 in after-hours trading.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Bristol-Myers, Pfizer's Eliquis approved in Japan

Dec 26, 2012

Regulators in Japan have approved sales of an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc., that's a potential blockbuster in a new category of medicines to prevent strokes and heart ...

Anti-clot drug recommended for new approval in EU

Sep 21, 2012

(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...

FDA adds new heart warning to Sanofi's Multaq

Dec 19, 2011

Federal health officials have added new safety warnings to the heart rhythm drug Multaq after company studies linked the pill to higher rates of heart attack, stroke and death in a subset of patients.

Recommended for you

Viagra ads target women for first time

17 hours ago

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments